Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Diseases
42%
Tenofovir
39%
Pharmacokinetics
30%
Coronavirinae
27%
Hydroxychloroquine
26%
Lamivudine
22%
Clinical Trial
21%
Cryptococcal Meningitis
18%
Efavirenz
16%
Microbiome
13%
Emtricitabine
13%
Adverse Event
12%
Tenofovir Disoproxil
12%
Amphotericin B
11%
Dolutegravir
10%
Placebo
9%
Sertraline
9%
Clinical Pharmacy
9%
Virus Hepatitis
9%
Flucytosine
9%
Acquired Immune Deficiency Syndrome
9%
Pharmacodynamics
9%
Filobasidiella
8%
Infection
8%
Rilpivirine
7%
Maraviroc
7%
Malaria
7%
Minimum Inhibitory Concentration
7%
Human Immunodeficiency Virus Infection
7%
Medroxyprogesterone Acetate
7%
Chloroquine
6%
Host Factor
6%
Fluconazole
6%
Mixed Infection
6%
Clinical Study
6%
Cabotegravir
6%
Active Metabolite
6%
Drug-Drug Interaction
5%
Tuberculous Meningitis
5%
Clinical Pharmacology
5%
Pharmacotherapy
5%
Meningitis
5%
Tolerability
5%
Keyphrases
Pre-exposure Prophylaxis (PrEP)
41%
COVID-19
28%
Antiretroviral
24%
Cryptococcal Meningitis
23%
Hydroxychloroquine
22%
AIDS/HIV
21%
Uganda
16%
Tenofovir
16%
United States
14%
Randomized Trial
13%
Lamivudine
13%
HIV Prevention
12%
Clinical Trials
12%
Vaginal Microbiota
11%
Tenofovir Diphosphate
11%
Ugandan
11%
Cerebrospinal Fluid
11%
Efavirenz
11%
Female Genital Tract
10%
Tenofovir Disoproxil Fumarate
10%
Pharmacokinetics
10%
Pharmacist
10%
Antiretroviral Therapy
9%
Cervical mucus
9%
HIV Medicine
9%
Viral Hepatitis
9%
Consensus Recommendations
9%
Academy
9%
American College of Clinical Pharmacy
9%
Antiretroviral Exposure
9%
Long-acting Antiretroviral Therapy
9%
Infectious Disease Specialist
9%
Recommendations for Use
9%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
8%
Placebo
7%
Drug Exposure
7%
Virus
6%
Dried Blood Spots
6%
Randomized Placebo-controlled Trial
6%
Medroxyprogesterone Acetate
6%
Pharmacology
6%
Cervical Tissue
6%
Autopsy
6%
Amphotericin B
6%
HIV Treatment
5%
Human Immunodeficiency Virus Type 1 (HIV-1)
5%
Hormonal Contraception
5%
Adverse Events
5%
Decedents
5%
Opioid Use Disorder
5%
Medicine and Dentistry
Human Immunodeficiency Virus
48%
Pre-Exposure Prophylaxis
22%
Cryptococcal Meningitis
18%
COVID-19
16%
Lamivudine
14%
Tenofovir
14%
Tenofovir Disoproxil
9%
Hydroxychloroquine
9%
Microbiome
9%
Dried Blood Spot
9%
Placebo
8%
Clinical Trial
7%
Depo-Provera
7%
Medroxyprogesterone Acetate
7%
Severe Acute Respiratory Syndrome Coronavirus 2
7%
Emtricitabine
6%
Antiretroviral Therapy
6%
Adverse Event
5%
Hazard Ratio
5%
Post-Exposure Prophylaxis
5%
Pharmacokinetics
5%
Diseases
5%